O metabolismo de apolipoproteínas e lipoproteínas na doença de Parkinson
Article Sidebar
Main Article Content
Abstract
Revisar os recentes avanços sobre o estudo do metabolismo de apolipoproteínas e lipoproteínas e sua associação na Doença de Parkinson (DP), a segunda doença neurodegenerativa mais comum que afeta principalmente a população idosa. Foi realizada uma revisão literária através de artigos científicos das bases de dados Pubmed, Science Direct, Scopus e Scielo. A seleção dos artigos considerou aqueles mais relevantes de acordo com a abrangência do tema proposto, de forma não sistemática. Foram selecionados 24 artigos entre 2010 a 2018 que discutiam DP com metabolismo de apolipoproteínas e lipoproteínas. Apoliproteinas e lipoproteínas podem contribuir como biomarcadores para o desenvolvimento, progressão e diagnóstico de DP, entretanto estudos adicionais são necessários para elucidar os mecanismos envolvidos na associação entre o metabolismo e o risco da doença.
Downloads
Article Details
• The author (s) warrant that the contribution is original and unpublished and that it is not in the process of being evaluated in other journal (s);
• The journal is not responsible for the opinions, ideas and concepts issued in the texts, as they are the sole responsibility of the author (s);
• Publishers have the right to make textual adjustments and to adapt the article to the rules of publication.
Authors retain the copyright and grant the journal the right of first publication, with the work simultaneously licensed under the Creative Commons Attribution License, which allows the sharing of work with acknowledgment of authorship and initial publication in this journal.
Authors are authorized to take additional contracts separately, for non-exclusive distribution of the version of the work published in this journal (eg publish in institutional repository or as book chapter), with acknowledgment of authorship and initial publication in this journal.
Authors are allowed and encouraged to publish and distribute their work online (eg in institutional repositories or on their personal page) at any point before or during the editorial process, as this can generate productive changes as well as increase the impact and citation of the published work (See The Effect of Free Access) at http://opcit.eprints.org/oacitation-biblio.html
References
ACHARIYAR, T. M. et al. Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation. Molecular Neurodegeneration, v. 11, n. 1, p. 74, 8 dez. 2016.
BACH, J.-P. et al. Projected numbers of people with movement disorders in the years 2030 and 2050. Movement Disorders, v. 26, n. 12, p. 2286–2290, out. 2011.
BALES, K. R. Brain lipid metabolism, apolipoprotein E and the pathophysiology of Alzheimer’s disease. Neuropharmacology, v. 59, n. 4–5, p. 295–302, set. 2010.
BAR-ON, P. et al. Effects of the cholesterol-lowering compound methyl-β-cyclodextrin in models of α-synucleinopathy. Journal of Neurochemistry, v. 98, n. 4, p. 1032–1045, ago. 2006.
CAROD-ARTAL, F. J.; VARGAS, A. P.; MARTINEZ-MARTIN, P. Determinants of quality of life in Brazilian patients with Parkinson’s disease. Movement Disorders, v. 22, n. 10, p. 1408–1415, 30 jul. 2007.
CHAHINE, L. M.; STERN, M. B.; CHEN-PLOTKIN, A. Blood-based biomarkers for Parkinson’s disease. Parkinsonism & Related Disorders, v. 20, p. S99–S103, jan. 2014.
CHAPUIS, S. et al. Impact of the motor complications of Parkinson’s disease on the quality of life. Movement Disorders, v. 20, n. 2, p. 224–230, fev. 2005.
DELENCLOS, M. et al. Biomarkers in Parkinson’s disease: Advances and strategies. Parkinsonism & Related Disorders, v. 22, p. S106–S110, jan. 2016.
ELLIOTT, D. A.; WEICKERT, C. S.; GARNER, B. Apolipoproteins in the brain: implications for neurological and psychiatric disorders. Clinical lipidology, v. 51, n. 4, p. 555–573, 1 ago. 2010.
EMAMZADEH, F. N. et al. Effects of different isoforms of apoE on aggregation of the α‐synuclein protein implicated in Parkinson’s disease. Neuroscience Letters, v. 618, p. 146–151, 8 abr. 2016.
FAHN, S. et al. Levodopa and the Progression of Parkinson’s Disease. New England Journal of Medicine, v. 351, n. 24, p. 2498–2508, 9 dez. 2004.
FERREIRA, J. J. et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. European Journal of Neurology, v. 20, n. 1, p. 5–15, jan. 2013.
FILIPPIN, N. T. et al. Qualidade de vida de sujeitos com doença de Parkinson e seus cuidadores. Fisioterapia em Movimento, v. 27, n. 1, p. 57–66, mar. 2014.
GOETZ, C. G. The History of Parkinson’s Disease: Early Clinical Descriptions and Neurological Therapies. Cold Spring Harbor Perspectives in Medicine, v. 1, n. 1, p. a008862–a008862, 1 set. 2011.
GREGÓRIO, M. L. et al. Impact of Genetic Variants of Apolipoprotein E on Lipid Profile in Patients with Parkinson’s Disease. BioMed Research International, v. 2013, p. 1–7, 2013.
GUERRA, A. C. L. C.; CALDAS, C. P. Dificuldades e recompensas no processo de envelhecimento: a percepção do sujeito idoso. Ciência & Saúde Coletiva, v. 15, n. 6, p. 2931–2940, set. 2010.
HUGHES, A. J. et al. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain, v. 125, n. 4, p. 861–870, abr. 2002.
INSTITUTO BRASILEIRO DE GEOGRAFIA E ESTATÍSTICA (IBGE). Censo Demográfico 2010. Disponível em: <https://ww2.ibge.gov.br/home/estatistica/populacao/censo2010/default.shtm>. Acesso em: 3 jul. 2019.
JANKOVIC, J. Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery & Psychiatry, v. 79, n. 4, p. 368–376, 1 abr. 2008.
KOOB, A. O. et al. Lovastatin ameliorates α-synuclein accumulation and oxidation in transgenic mouse models of α-synucleinopathies. Experimental Neurology, v. 221, n. 2, p. 267–274, fev. 2010.
KWITEROVICH, P. O. The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review. The American journal of cardiology, v. 86, n. 12A, p. 5L-10L, 21 dez. 2000.
MAGRINELLI, F. et al. Pathophysiology of Motor Dysfunction in Parkinson’s Disease as the Rationale for Drug Treatment and Rehabilitation. Parkinson’s Disease, v. 2016, p. 1–18, 2016.
MARTÍNEZ-MARTÍN, P. et al. Parkinson’s disease severity levels and MDS-Unified Parkinson’s Disease Rating Scale. Parkinsonism & Related Disorders, v. 21, n. 1, p. 50–54, jan. 2015.
MEISSNER, W. G. et al. Priorities in Parkinson’s disease research. Nature Reviews Drug Discovery, v. 10, n. 5, p. 377–393, 29 maio 2011.
MINERS, J. S.; CLARKE, P.; LOVE, S. Clusterin levels are increased in Alzheimer’s disease and influence the regional distribution of A β. Brain Pathology, v. 27, n. 3, p. 305–313, maio 2017.
MOHAMMADPOUR LASHKARI, F. et al. The association between (8390G>A) single nucleotide polymorphism in APOE gene with Alzheimer’s and Parkinson disease. Egyptian Journal of Medical Human Genetics, v. 17, n. 2, p. 185–189, 1 abr. 2016.
MOORE, D. J. et al. Molecular pathophysiology of Parkinson’s disease. Annual Review of Neuroscience, v. 28, n. 1, p. 57–87, 21 jul. 2005.
NAVARRO, A. et al. Lifelong Expression of Apolipoprotein D in the Human Brainstem: Correlation with Reduced Age-Related Neurodegeneration. PLoS ONE, v. 8, n. 10, p. e77852, 22 out. 2013.
NIEUWBOER, A.; ROCHESTER, L.; JONES, D. Cueing Gait and Gait-related Mobility in Patients With Parkinsonʼs Disease. Topics in Geriatric Rehabilitation, v. 24, n. 2, p. 151–165, abr. 2008.
PEREIRA, D.; GARRETT, C. Risk factors for Parkinson disease: an epidemiologic study. Acta Médica Portuguesa, v. 23, n. 1, p. 15–24, 2010.
PETERNELLA, F. M. N.; MARCON, S. S. Descobrindo a Doença de Parkinson: impacto para o parkinsoniano e seu familiar. Revista Brasileira de Enfermagem, v. 62, n. 1, p. 25–31, fev. 2009.
POEWE, W. The natural history of Parkinson’s disease. Journal of Neurology, v. 253, n. S7, p. vii2–vii6, dez. 2006.
PŘIKRYLOVÁ VRANOVÁ, H. et al. CSF markers of neurodegeneration in Parkinson’s disease. Journal of Neural Transmission, v. 117, n. 10, p. 1177–1181, 21 out. 2010.
QIANG, J. K. et al. Plasma apolipoprotein A1 as a biomarker for Parkinson disease. Annals of Neurology, v. 74, n. 1, p. 119–127, jul. 2013.
RAICHLEN, D. A.; ALEXANDER, G. E. Exercise, APOE genotype, and the evolution of the human lifespan. Trends in Neurosciences, v. 37, n. 5, p. 247–255, maio 2014.
RBEIRO, K. C.; SHINTAKU, R. DE C. O. A influência dos lipídios da dieta sobre a aterosclerose. ConScientiae Saúde, v. 3, p. 73–83, 2004.
RITZ, B. et al. Statin use and Parkinson’s disease in Denmark. Movement Disorders, v. 25, n. 9, p. 1210–1216, 15 jul. 2010.
SCHRAG, A.; BEN-SHLOMO, Y.; QUINN, N. How valid is the clinical diagnosis of Parkinson’s disease in the community? Journal of Neurology, Neurosurgery & Psychiatry, v. 73, n. 5, p. 529–534, 1 nov. 2002.
SCHULZ-SCHAEFFER, W. J. The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia. Acta Neuropathologica, v. 120, n. 2, p. 131–143, 20 ago. 2010.
SHULTS, C. W. Lewy bodies. Proceedings of the National Academy of Sciences, v. 103, n. 6, p. 1661–1668, 7 fev. 2006.
SINGH, N. K. et al. APOE and LRPAP1 gene polymorphism and risk of Parkinson’s disease. Neurological Sciences, v. 35, n. 7, p. 1075–1081, 7 jul. 2014.
STEFANIS, L. α-Synuclein in Parkinson’s disease. Cold Spring Harbor Perspectives in Medicine, v. 2, n. 2, p. a009399–a009399, 1 fev. 2012.
SWANSON, C. R. et al. Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson’s disease patients. Movement Disorders, v. 30, n. 12, p. 1648–1656, out. 2015.
TAMAM, Y. et al. Association of apolipoprotein E genotypes with prognosis in multiple sclerosis. European review for medical and pharmacological sciences, v. 15, n. 10, p. 1122–30, out. 2011.
THEENDAKARA, V. et al. Neuroprotective Sirtuin ratio reversed by ApoE4. Proceedings of the National Academy of Sciences, v. 110, n. 45, p. 18303–18308, 5 nov. 2013.
VITALI, C.; WELLINGTON, C. L.; CALABRESI, L. HDL and cholesterol handling in the brain. Cardiovascular Research, v. 103, n. 3, p. 405–413, 1 ago. 2014.
WALDNER, A. et al. Apolipoprotein D Concentration in Human Plasma during Aging and in Parkinson’s Disease: A Cross-Sectional Study. Parkinson’s Disease, v. 2018, p. 1–7, 2018.
WANG, E.-S. et al. Tetranectin and apolipoprotein A-I in cerebrospinal fluid as potential biomarkers for Parkinson’s disease. Acta Neurologica Scandinavica, jan. 2010.
WEI, Q. et al. Reduced Serum Levels of Triglyceride, Very Low Density Lipoprotein Cholesterol and Apolipoprotein B in Parkinson’s Disease Patients. PLoS ONE, v. 8, n. 9, p. e75743, 26 set. 2013.
WEINTRAUB, D.; COMELLA, C. L.; HORN, S. Parkinson’s disease--Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment. The American journal of managed care, v. 14, n. 2 Suppl, p. S40-8, mar. 2008.
WOOD, W. G. et al. Statins and neuroprotection. Annals of the New York Academy of Sciences, v. 1199, n. 1, p. 69–76, jun. 2010.
YANG, X.-P. et al. Scavenger receptor-BI is a receptor for lipoprotein(a). Journal of Lipid Research, v. 54, n. 9, p. 2450–2457, set. 2013.
ZHANG, J.; LIU, Q. Cholesterol metabolism and homeostasis in the brain. Protein & cell, v. 6, n. 4, p. 254–64, abr. 2015.